JP2014518252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518252A5 JP2014518252A5 JP2014517915A JP2014517915A JP2014518252A5 JP 2014518252 A5 JP2014518252 A5 JP 2014518252A5 JP 2014517915 A JP2014517915 A JP 2014517915A JP 2014517915 A JP2014517915 A JP 2014517915A JP 2014518252 A5 JP2014518252 A5 JP 2014518252A5
- Authority
- JP
- Japan
- Prior art keywords
- cough
- condition
- respiratory
- oral composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011224 Cough Diseases 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 12
- 230000000241 respiratory Effects 0.000 claims 9
- 230000000954 anitussive Effects 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 206010060954 Abdominal hernia Diseases 0.000 claims 3
- 206010013952 Dysphonia Diseases 0.000 claims 3
- 206010019909 Hernia Diseases 0.000 claims 3
- 208000010473 Hoarseness Diseases 0.000 claims 3
- 206010022437 Insomnia Diseases 0.000 claims 3
- 206010028334 Muscle spasms Diseases 0.000 claims 3
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 3
- 208000010487 Rib Fractures Diseases 0.000 claims 3
- 208000005392 Spasm Diseases 0.000 claims 3
- 210000003802 Sputum Anatomy 0.000 claims 3
- 206010042772 Syncope Diseases 0.000 claims 3
- 210000001186 Vagus Nerve Anatomy 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 206010047924 Wheezing Diseases 0.000 claims 3
- 230000013872 defecation Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000027939 micturition Effects 0.000 claims 3
- 230000036262 stenosis Effects 0.000 claims 3
- 200000000009 stenosis Diseases 0.000 claims 3
- 208000006673 Asthma Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 2
- 206010006451 Bronchitis Diseases 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 206010008685 Chondritis Diseases 0.000 claims 2
- 208000000059 Dyspnea Diseases 0.000 claims 2
- 206010013975 Dyspnoeas Diseases 0.000 claims 2
- 210000000613 Ear Canal Anatomy 0.000 claims 2
- 208000009471 Gastroesophageal Reflux Diseases 0.000 claims 2
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 208000009856 Lung Disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010057190 Respiratory tract infection Diseases 0.000 claims 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims 2
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims 2
- 239000003434 antitussive agent Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000000271 cardiovascular Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000011109 contamination Methods 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 239000003172 expectorant agent Substances 0.000 claims 2
- 201000006860 gastroesophageal reflux disease Diseases 0.000 claims 2
- 230000002650 habitual Effects 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 2
- 231100000486 side effect Toxicity 0.000 claims 2
- 230000000391 smoking Effects 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010008479 Chest pain Diseases 0.000 claims 1
- 206010010719 Conjunctival haemorrhage Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000002173 Dizziness Diseases 0.000 claims 1
- 206010013781 Dry mouth Diseases 0.000 claims 1
- 229940066493 Expectorants Drugs 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- 210000000578 Peripheral Nerves Anatomy 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010066218 Stress urinary incontinence Diseases 0.000 claims 1
- 229960004559 Theobromine Drugs 0.000 claims 1
- 201000008908 Tietze's syndrome Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000002421 anti-septic Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001149 cognitive Effects 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 230000003628 erosive Effects 0.000 claims 1
- 230000003419 expectorant Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 230000000631 nonopiate Effects 0.000 claims 1
- 201000005111 ocular hyperemia Diseases 0.000 claims 1
- 230000001144 postural Effects 0.000 claims 1
- 230000000506 psychotropic Effects 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 235000007586 terpenes Nutrition 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Claims (18)
- 治療的有効量のテオブロミンと、鎮咳活性を有する複数の追加的な治療化合物とを含む経口組成物。
- 前記鎮咳活性を有する複数の治療化合物は、非オピエート系鎮咳剤、オピエート系鎮咳剤、うっ血除去剤、去痰剤、粘液溶解剤、抗ヒスタミン剤、非ステロイド性抗炎症薬(NSAID)、神経因性疼痛剤、テルペン、ACE阻害剤、アンジオテンシンII受容体拮抗剤、またはこれらのいずれかの組合せを含む、請求項1に記載の経口組成物。
- 前記鎮咳活性は、咳に関連する迷走神経機能を抑制し、咳に関連する中枢神経機能を抑制し、および/または咳に関連する末梢神経機能を抑制する、請求項1または2に記載の経口組成物。
- 前記鎮咳活性は望ましくない副作用を伴わない、請求項1〜3のいずれか1項に記載の経口組成物。
- 前記望ましくない副作用は、鎮静、認知性の混迷、眩暈、眠気、体位性高血圧、協調困難、脱力、振戦、呼吸抑制、向精神作用、睡眠障害、無用な想望感、CNS刺激、体重増加、食欲変化、性機能の変化、便秘、口渇、腸びらん、胃潰瘍、腎臓炎症、心血管高血圧、心血管刺激、高クリミナ、外出不能、胸部痛、腹圧性尿失禁、またはこれらのいずれかの組合せを含む、請求項4に記載の経口組成物。
- 前記鎮咳活性は、咳嗽状態に関連する症状を低減させる、請求項1〜5のいずれか1項に記載の経口組成物。
- 前記症状は、咳の頻度、咳の重症度、咳の音量もしくは騒音レベル、嗄声、咽喉痛、呼吸困難、呼吸器うっ血、喘鳴、呼吸器狭窄、呼吸器炎症、咳に関連する筋痙攣、痰産生、失神、不眠、嘔吐、結膜下出血(赤目)、咳嗽排便、咳嗽排尿、腹部ヘルニア、骨盤部ヘルニア、肋軟骨炎、または下部肋骨骨折を含む、請求項6に記載の経口組成物。
- 前記鎮咳活性は、急性咳嗽状態、亜急性咳嗽状態、慢性咳嗽状態、乾性咳嗽状態、湿性咳嗽状態、または疾患もしくは障害に関連する咳嗽を抑制する、請求項1〜7のいずれか1項に記載の経口組成物。
- 咳嗽状態の治療用の、請求項1〜8のいずれか1項に記載の経口組成物。
- 前記咳嗽状態は、急性咳嗽状態、亜急性咳嗽状態、慢性咳嗽状態、乾性咳嗽状態、湿性咳嗽状態、または疾患もしくは障害に関連する咳嗽を含む、請求項9に記載の経口組成物。
- 前記疾患または障害は、喘息、アトピー咳嗽、気管支炎、胃食道逆流症、呼吸器の感染、炎症、薬剤負荷、汚染、後鼻漏、喫煙事象、迷走神経刺激、外耳道の疾患、肺疾患、肺腫瘍、習慣性咳嗽、チック症状、トウレット症候群、心血管疾患、または感染後咳嗽である、請求項10に記載の経口組成物。
- 前記治療は咳嗽状態に関連する症状を低減させる、請求項9〜11のいずれか1項に記載の経口組成物。
- 前記症状は、咳、嗄声、咽喉痛、呼吸困難、呼吸器うっ血、喘鳴、呼吸器狭窄、呼吸器炎症、咳に関連する筋痙攣、痰産生、失神、不眠、嘔吐、結膜下出血、咳嗽排便、咳嗽排尿、腹部ヘルニア、骨盤部ヘルニア、肋軟骨炎、下部肋骨骨折、またはこれらのいずれかの組合せを含む、請求項12に記載の経口組成物。
- 咳嗽状態の治療用の医薬の製造における、請求項1〜8のいずれか1項に記載の経口組成物の使用。
- 前記咳嗽状態は、急性咳嗽状態、亜急性咳嗽状態、慢性咳嗽状態、乾性咳嗽状態、湿性咳嗽状態、または疾患もしくは障害に関連する咳を含む、請求項14に記載の使用。
- 前記疾患または障害は、喘息、アトピー咳嗽、気管支炎、胃食道逆流症、呼吸器の感染、炎症、薬剤負荷、汚染、後鼻漏、喫煙事象、迷走神経刺激、外耳道の疾患、肺疾患、肺腫瘍、習慣性咳嗽、チック症状、トウレット症候群、心血管疾患、または感染後咳嗽である、請求項15に記載の使用。
- 前記治療は咳嗽状態に関連する症状を低減させる、請求項14〜16のいずれか1項に記載の使用。
- 前記症状は、咳、嗄声、咽喉痛、呼吸困難、呼吸器うっ血、喘鳴、呼吸器狭窄、呼吸器炎症、咳に関連する筋痙攣、痰産生、失神、不眠、嘔吐、結膜下出血、咳嗽排便、咳嗽排尿、腹部ヘルニア、骨盤部ヘルニア、肋軟骨炎、下部肋骨骨折、またはこれらのいずれかの組合せを含む、請求項17に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1111485.7 | 2011-07-05 | ||
GBGB1111485.7A GB201111485D0 (en) | 2011-07-05 | 2011-07-05 | Drug composition and its use in therapy |
PCT/GB2012/050816 WO2013004999A1 (en) | 2011-07-05 | 2012-04-13 | Drug combinations and uses in treating a coughing condition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017212821A Division JP2018048189A (ja) | 2011-07-05 | 2017-11-02 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014518252A JP2014518252A (ja) | 2014-07-28 |
JP2014518252A5 true JP2014518252A5 (ja) | 2015-05-21 |
Family
ID=44512137
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014517915A Pending JP2014518252A (ja) | 2011-07-05 | 2012-04-13 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
JP2017212821A Pending JP2018048189A (ja) | 2011-07-05 | 2017-11-02 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017212821A Pending JP2018048189A (ja) | 2011-07-05 | 2017-11-02 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP3251665A1 (ja) |
JP (2) | JP2014518252A (ja) |
KR (1) | KR101676454B1 (ja) |
CN (1) | CN103648488A (ja) |
AU (2) | AU2012280019B2 (ja) |
BR (1) | BR112014000159A2 (ja) |
CA (1) | CA2840793A1 (ja) |
GB (1) | GB201111485D0 (ja) |
MX (1) | MX2014000129A (ja) |
RU (2) | RU2014103787A (ja) |
WO (1) | WO2013004999A1 (ja) |
ZA (1) | ZA201400010B (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
GB201014391D0 (en) * | 2010-08-27 | 2010-10-13 | Biocopea Ltd | Drug composition and its use in therapy |
GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
GB0910375D0 (en) | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
JP2016518388A (ja) | 2013-04-30 | 2016-06-23 | オティトピック インク. | 乾燥粉末配合および使用方法 |
MX2017002948A (es) * | 2014-09-08 | 2017-08-15 | Gotham Biopharmaceuticals Inc | Métodos de tratamiento para la sarcoidosis pulmonar. |
CN104436176A (zh) * | 2014-11-17 | 2015-03-25 | 华东理工大学 | 一种基于上呼吸道感染及肺炎用的新型生物抗菌喷雾剂 |
JP7493449B2 (ja) | 2017-09-22 | 2024-05-31 | ヴェクチュラ インコーポレイテッド | ステアリン酸マグネシウムを含む乾燥粉末組成物 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
CN109793823A (zh) * | 2017-11-17 | 2019-05-24 | 中国科学院大连化学物理研究所 | 一种外用止咳平喘软膏剂及其制备方法 |
CN112703000B (zh) * | 2018-07-23 | 2024-05-31 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
US20240122934A1 (en) * | 2019-10-16 | 2024-04-18 | University Of South Florida | Compositions and methods of treatment for inhibiting capillary tube regression |
US20230346761A1 (en) * | 2019-12-31 | 2023-11-02 | The Trustees Of Indiana University | Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5 |
US11628165B1 (en) * | 2020-03-25 | 2023-04-18 | Helen Feng | Method of boosting immune system against viral infection |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US20020009478A1 (en) * | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
JP2002363072A (ja) * | 2001-04-03 | 2002-12-18 | Taisho Pharmaceut Co Ltd | 鎮咳用組成物 |
JP2003081821A (ja) * | 2001-09-12 | 2003-03-19 | Taisho Pharmaceut Co Ltd | 医薬組成物 |
JP4377564B2 (ja) * | 2002-05-02 | 2009-12-02 | ロート製薬株式会社 | 内服用組成物 |
US6979689B2 (en) * | 2002-12-20 | 2005-12-27 | Pediamed Pharmaceuticals, Inc. | Compositions and methods for treating upper respiratory congestion |
US20050152967A1 (en) * | 2003-03-28 | 2005-07-14 | Pfab, Lp | Dynamic variable release |
JP2007518804A (ja) | 2004-01-20 | 2007-07-12 | アラーガン、インコーポレイテッド | トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物 |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
JP4195895B2 (ja) * | 2006-04-04 | 2008-12-17 | 小林製薬株式会社 | 吐出装置を備えた容器に収容される経口投与用液体医薬製剤 |
US20080003280A1 (en) * | 2006-06-26 | 2008-01-03 | Levine Brian M | Combination cough treatment compounds and method of treating common coughs |
WO2010123946A2 (en) | 2009-04-20 | 2010-10-28 | Allergan, Inc. | Silk fibroin hydrogels and uses thereof |
GB0919889D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
GB0919893D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
GB0921805D0 (en) * | 2009-12-14 | 2010-01-27 | Biocopea Ltd | Drug composition and its use in therapy |
GB0921803D0 (en) * | 2009-12-14 | 2010-01-27 | Biocopea Ltd | Drug composition and its use in therapy |
GB201014391D0 (en) * | 2010-08-27 | 2010-10-13 | Biocopea Ltd | Drug composition and its use in therapy |
UA47594U (uk) * | 2009-09-17 | 2010-02-10 | Игорь Викторович Трутаев | Комбінований засіб для лікування та профілактики захворювань дихальних шляхів |
JP5815226B2 (ja) * | 2009-11-30 | 2015-11-17 | 興和株式会社 | ロキソプロフェンを含有する医薬組成物 |
-
2011
- 2011-07-05 GB GBGB1111485.7A patent/GB201111485D0/en not_active Ceased
-
2012
- 2012-04-13 JP JP2014517915A patent/JP2014518252A/ja active Pending
- 2012-04-13 EP EP17177202.3A patent/EP3251665A1/en not_active Withdrawn
- 2012-04-13 EP EP12716069.5A patent/EP2729136A1/en not_active Withdrawn
- 2012-04-13 RU RU2014103787/15A patent/RU2014103787A/ru unknown
- 2012-04-13 MX MX2014000129A patent/MX2014000129A/es unknown
- 2012-04-13 BR BR112014000159-6A patent/BR112014000159A2/pt not_active IP Right Cessation
- 2012-04-13 KR KR1020147002930A patent/KR101676454B1/ko active IP Right Grant
- 2012-04-13 CA CA2840793A patent/CA2840793A1/en not_active Abandoned
- 2012-04-13 RU RU2016101054A patent/RU2016101054A/ru unknown
- 2012-04-13 CN CN201280033545.1A patent/CN103648488A/zh active Pending
- 2012-04-13 AU AU2012280019A patent/AU2012280019B2/en not_active Ceased
- 2012-04-13 WO PCT/GB2012/050816 patent/WO2013004999A1/en active Application Filing
-
2014
- 2014-01-06 ZA ZA2014/00010A patent/ZA201400010B/en unknown
-
2016
- 2016-11-09 AU AU2016256741A patent/AU2016256741A1/en not_active Abandoned
-
2017
- 2017-11-02 JP JP2017212821A patent/JP2018048189A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014518252A5 (ja) | ||
RU2014103787A (ru) | Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем | |
Craig et al. | The correlation between allergic rhinitis and sleep disturbance | |
JP2010168404A (ja) | 睡眠時無呼吸の薬理学的処置 | |
JP2005506370A5 (ja) | ||
JP2017528507A5 (ja) | ||
RU2005137165A (ru) | Применение соединения для лечения нарушений сна | |
JP2011503045A (ja) | Crth2拮抗化合物の使用 | |
JP2023076465A5 (ja) | ||
WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
JP2006523216A5 (ja) | ||
JP2007533687A5 (ja) | ||
JP2011504474A5 (ja) | ||
JP2009537553A5 (ja) | ||
JP2008516909A5 (ja) | ||
US20170312282A1 (en) | Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof | |
US20100204205A1 (en) | Tolerability of mirtazapine and a second active agent by using them in combination | |
JP2016507500A5 (ja) | ||
WO2006115135A1 (ja) | 過敏性腸症候群治療剤 | |
JP2005512946A5 (ja) | ||
JP2011500589A5 (ja) | ||
KR20150011379A (ko) | 옥시부티닌 투여를 위한 방법 및 조성물 | |
US20170151222A1 (en) | Snoring treatment | |
JP5634529B2 (ja) | 強迫性障害(ocd)処置用の薬剤の製造のためのアゴメラチンの使用 | |
WO2023158424A1 (en) | Novel pharmaceutical compositions and methods for treatment of insomnia |